SCHEMBL19950281

SCHEMBL19950281

Cn1cc(-c2nn(C(=O)O)c3cnc(-c4c(F)cc(N)cc4OC(F)F)cc23)cn1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 9/20 0.39
NTRK1 P04629 4/20 0.38
KIT P10721 4/20 0.38
FLT3 P36888 4/20 0.38
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
MERTK Q12866 4/20 0.33
TYRO3 Q06418 4/20 0.33
AXL P30530 3/20 0.33
KCNH2 Q12809 1/20 0.33
PIM1 P11309 1/20 0.32
SIK1 P57059 1/20 0.32
SIK2 Q9H0K1 1/20 0.32
SIK3 Q9Y2K2 1/20 0.32
MAPK1 P28482 1/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CG P48736 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19950530 0.91 MAP4K1 (0.47) MAP4K1NTRK1KITFLT3PIM1
SCHEMBL19950513 0.90 MAP4K1 (0.37) MAP4K1NTRK1KITFLT3ALOX5AP
SCHEMBL29746418 0.90 MAP4K1 (0.37) MAP4K1NTRK1KITFLT3ALOX5AP
SCHEMBL19950443 0.90 MAP4K1 (0.43) MAP4K1NTRK1KITFLT3ALOX5AP
SCHEMBL19950144 0.86 MAP4K1 (0.45) MAP4K1NTRK1KITFLT3ALOX5AP
SCHEMBL19950714 0.85 MAP4K1 (0.38) MAP4K1NTRK1KITFLT3MERTK
SCHEMBL19950686 0.80 MAP4K1 (0.44) MAP4K1NTRK1KITFLT3PIM1
SCHEMBL29746578 0.80 MAP4K1 (0.44) MAP4K1NTRK1KITFLT3PIM1
SCHEMBL19950639 0.79 MAP4K1 (0.40) MAP4K1NTRK1KITFLT3ALOX5AP
SCHEMBL29746725 0.79 MAP4K1 (0.40) MAP4K1NTRK1KITFLT3ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-10934288-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2021-03-02 US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 US disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-10934288-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885NTRK1 2377/4885KIT 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.